SoQut – Imaging

SoQut Imaging is revolutionizing liver disease diagnosis through MRI. Our exclusive technology, Elibio®, provides a non-invasive “digital biopsy” based on a patented method.

MASH, a severe complication of hepatic steatosis affecting 1 in 20 adults worldwide, progresses silently until cirrhosis or cancer develops. Patients are often unaware they are ill, and diagnosis is complex, involving non-specific tests and risky, costly biopsies. Founded in 2021, SoQut Imaging is a deeptech company based in Bordeaux that develops Elibio®, a SaaS technology delivering the precision of a biopsy without its risks or costs and in a non-invasive way. Already tested on over 200 patients, Elibio® seamlessly integrates into the patient’s radiological pathway, providing reliable and rapid diagnostic information for hepatologists.